<?xml version="1.0" encoding="UTF-8"?>
<p id="p0180">Through VirusMINT database enrichment analysis, it was observed that the targets of both the HMP bioactives and SARS-CoV-2 are also targeted by Human Immunodeficiency Virus 1 (
 <xref rid="fig8" ref-type="fig">Fig. 8</xref>B). Additionally, human protein targets of Hepatitis C and Influenza A were also observed for the bioactive targets. Anti-viral drugs used in the treatment of these diseases are being used against SARS-CoV-2 [
 <xref rid="bib49" ref-type="bibr">49</xref>]. This further proposes that the selected HMP bioactives can likely be used against SARS-CoV-2 and control other viral RNA infections.
</p>
